Semaglutide vs Ozempic & Wegovy in 2026

Semaglutide is a GLP-1 peptide. Ozempic and Wegovy are two FDA-approved branded medicines from Novo Nordisk that both use semaglutide, and compounded semaglutide is an individualized medicine that a licensed physician prescribes and a state-licensed 503A pharmacy fills for one named patient. What actually separates them is FDA status, who makes them, how you get them, the oversight behind them, and whether the price is transparent. This page walks through each one so you can tell them apart in 2026.

Semaglutide, Ozempic, and Wegovy are not the same thing

Semaglutide is the peptide, and Ozempic and Wegovy are two branded products built on it. Semaglutide is a GLP-1 receptor agonist, a peptide that mimics a gut hormone your body already makes to help regulate blood sugar and appetite. Novo Nordisk turned that peptide into finished, FDA-approved drugs sold under two brand names for two different uses.

• Semaglutide: the GLP-1 peptide itself, and the active molecule inside every product below. GLP-1 medicines like semaglutide are peptides, which is exactly the category pru focuses on.
• Ozempic: Novo Nordisk's semaglutide product FDA-approved for type 2 diabetes, and for reducing the risk of major cardiovascular events and kidney decline in certain adults. It is a once-weekly injection.
• Wegovy: Novo Nordisk's semaglutide product FDA-approved for chronic weight management in adults and in children 12 and older with obesity, and for reducing cardiovascular risk in adults with overweight or obesity. Also once-weekly injection.

So Ozempic and Wegovy share the same drug but carry different FDA indications, different maximum doses, and different labels. Compounded semaglutide is a fourth thing entirely, covered further down.

Ozempic and Wegovy differ by FDA indication and dose, not by drug

Ozempic and Wegovy both use semaglutide, but the FDA approved them for different reasons at different doses. Ozempic is the diabetes and cardiovascular-and-kidney-risk brand, dosed up to 2.0 mg once weekly. Wegovy is the weight-management brand, and in 2026 its options widened.

• Ozempic is FDA-approved for type 2 diabetes, and to reduce cardiovascular event risk and slow kidney function decline in certain patients. Weekly injection, titrated up to 2.0 mg.
• Wegovy is FDA-approved for chronic weight management, weekly injection titrated up to 2.4 mg. In 2026 the FDA approved a higher-dose Wegovy HD at 7.2 mg.
• A once-daily oral Wegovy pill (25 mg) was FDA-approved on December 22, 2025 and began reaching pharmacies in early 2026, the first oral GLP-1 approved for weight loss.

If your question is really Ozempic vs Wegovy: they are two brands of the same Novo Nordisk drug approved for different jobs. Your prescriber matches the product and dose to your situation, not the other way around.

Compounded semaglutide is a distinct, individualized, prescribed medicine

Compounded semaglutide is a distinct, individualized medicine, not the same as a branded product. A licensed pharmacy makes it for one named patient on a valid prescription from a licensed physician. It is pharmacy-grade and prescribed, but not FDA-approved, because compounded medicines by definition are not the finished, mass-produced products the FDA reviews and approves. Compare it to the branded drugs on access, cost, and oversight, not on being the same drug.

The legitimate route in 2026 is individualized 503A compounding. A state-licensed 503A pharmacy can prepare semaglutide for a specific patient based on that patient's prescription. What the law does not allow is mass production of drugs that are essentially copies of a commercially available product.

After the FDA declared the semaglutide shortage resolved on February 21, 2025 and removed Ozempic and Wegovy from the shortage list, that mass-copy path wound down, with 503A pharmacies given until April 22, 2025 to stop compounding essentially-copy versions. Individualized, patient-specific 503A compounding on a real prescription remains the legitimate lane, and it is the only lane pru uses.

How compounded semaglutide gets described has also become a legal flashpoint: Novo Nordisk sued Hims & Hers on February 9, 2026 over its compounded semaglutide, and the two later announced a partnership in 2026 under which Hims would offer Novo's branded products.

Semaglutide vs Ozempic vs Wegovy vs compounded, at a glance

Here is how the four line up on the things that actually differ: what each one is, who makes it, FDA status, access, cost transparency, and oversight.

The real differences are access, individualization, transparency, and oversight, and that is where the choices actually feel different day to day.

What semaglutide costs, and how you get it

Brand-name GLP-1 medicines like Ozempic and Wegovy commonly run around $1,000 or more per month at the pharmacy counter without insurance. What you actually pay depends on your plan, and coverage for these drugs is uneven, so a lot of people end up facing close to the full cash price. That sticker is the reason many people go looking for another route in the first place.

pru takes a different shape on price. Instead of a list price with a markup baked in, pru runs on a flat membership of about $50 a month billed annually, and the compounded peptide is priced at cost and itemized. You see each piece: the pharmacy fill, supplies, shipping, and the consult. There is no markup on the medicine itself. This describes how pru prices the medicine, not how the compounded product performs. You can see the membership and at-cost pricing laid out plainly.

What the trials of the branded drugs show

The trial numbers people look for belong to the branded, FDA-approved drugs that were actually studied. In Novo Nordisk's STEP trials of Wegovy for chronic weight management, participants lost about 15% of their body weight on average over 68 weeks. In the SUSTAIN trial program, Novo Nordisk studied Ozempic for blood-sugar control and weight change in adults with type 2 diabetes. These are results for Novo Nordisk's branded, FDA-approved semaglutide products.

Why the compounding rules changed in 2025

The rules shifted in early 2025 for one concrete reason: the shortage ended. On February 21, 2025 the FDA declared the semaglutide injection shortage resolved and removed the product from its shortage list. While a drug is in shortage, pharmacies have more room to compound versions of it. Once the shortage is resolved, that extra room closes, and the compounding falls back to the ordinary rules. That is the trigger behind the 2025 change.

• 503A pharmacies are state-licensed pharmacies that compound a medicine for one named patient on a specific prescription. This is the individualized, patient-by-patient lane, and it stays legitimate whether or not a drug is in shortage. It is the only lane pru uses.
• 503B outsourcing facilities are FDA-registered and can compound in larger batches without a patient-specific prescription, which is what the shortage window had temporarily opened up for semaglutide.

When the shortage resolved, the FDA set wind-down dates for compounding versions that are essentially copies of the branded drugs: about April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. What did not change is the individualized route. A licensed physician can still write a prescription, and a state-licensed 503A pharmacy can still fill it for a specific patient. That patient-specific 503A path is the legitimate lane pru operates in, and you can read how compounded semaglutide works for the fuller picture.

How pru handles semaglutide

With pru, compounded semaglutide follows one clean, individualized path. A licensed physician reviews your intake and, if it's appropriate, writes a prescription. A state-licensed 503A pharmacy fills that prescription for you by name. You are never buying an anonymous vial. It's your own prescribed, pharmacy-grade medicine.

The part that's genuinely different is the money. pru runs on a flat membership of about $50 a month billed annually, and every peptide is priced at cost, itemized so you see each piece: the pharmacy fill, supplies, shipping, and the consult. There's no markup on the medicine itself.

You can see the membership and at-cost pricing laid out plainly, start with semaglutide, and if you want the dosing detail read how semaglutide is dosed or where compounded semaglutide comes from. Taking your metabolic health into your own hands is a smart, proactive move, and pru exists to make that informed choice the accessible one, with licensed physicians, pharmacy-grade medicine, and pricing shown at cost. When you are ready, take the next step. Peptides made simple, for everyone.

Related reading

• Semaglutide vs tirzepatide
• Compounded semaglutide, explained
• Semaglutide dosage and titration
• Semaglutide side effects and results
• see it on pru

Common questions